Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;15(2):120-132.
doi: 10.1038/nrcardio.2017.131. Epub 2017 Sep 7.

Expert consensus document: A 'diamond' approach to personalized treatment of angina

Affiliations
Free article
Review

Expert consensus document: A 'diamond' approach to personalized treatment of angina

Roberto Ferrari et al. Nat Rev Cardiol. 2018 Feb.
Free article

Abstract

In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine, nicorandil, ranolazine, trimetazidine), with the recommendation to reserve second-choice medications for patients who have contraindications to first-choice agents, do not tolerate them, or remain symptomatic. No direct comparisons between first-choice and second-choice treatments have demonstrated the superiority of one group of drugs over the other. Meta-analyses show that all antianginal drugs have similar efficacy in reducing symptoms, but provide no evidence for improvement in survival. The newer, second-choice drugs have more evidence-based clinical data that are more contemporary than is available for traditional first-choice drugs. Considering some drugs, but not others, to be first choice is, therefore, difficult. Moreover, double or triple therapy is often needed to control angina. Patients with angina can have several comorbidities, and symptoms can result from various underlying pathophysiologies. Some agents, in addition to having antianginal effects, have properties that could be useful depending on the comorbidities present and the mechanisms of angina, but the guidelines do not provide recommendations on the optimal combinations of drugs. In this Consensus Statement, we propose an individualized approach to angina treatment, which takes into consideration the patient, their comorbidities, and the underlying mechanism of disease.

PubMed Disclaimer

References

    1. Int J Cardiol. 2012 Nov 1;161(1):e7-9 - PubMed
    1. Circulation. 1994 Aug;90(2):726-34 - PubMed
    1. N Engl J Med. 1988 Aug 18;319(7):385-92 - PubMed
    1. JAMA. 1999 May 26;281(20):1927-36 - PubMed
    1. Expert Opin Drug Saf. 2006 Sep;5(5):667-74 - PubMed

Substances